Key Takeaways Hologic's buyout of up to $79 per share offers just 0.6% upside from recent levels.Align Technology hit $4B revenues in 2025, with aligner volumes rising 6.7% globally.DSO growth and digital tools adoption are boosting Align Technology's long-term expansion.Hologic (HOLX) and Align Technology (ALGN) are two well-established players in the medical technology (MedTech) market, each with distinct niche. Hologic develops diagnostics, surgical, and medical imaging technologies to advance women’s he ...

Based in Tempe, AZ, and founded in 1997, Align Technology, Inc. ( ALGN ) is a leading manufacturer of orthodontic treatments globally. They sell clear aligners under the Invisalign and Vivera brands as well as iTero scanners, alongsideI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I believe ...

Core Viewpoint - Align Technology is experiencing a potential stock boost as Elliott Investment Management has acquired a significant stake and plans to engage with the company to enhance its stock price [2]. Group 1: Stock Performance and Analyst Ratings - Align Technology shares have increased by 13% year-to-date, with a Relative Strength Rating of 76. The stock had previously fallen 83% from its peak of 737.45 in September 2021, bottoming at 122 in September [2]. - Barclays upgraded Align Technology to overweight from equal weight, maintaining a price target of 200, citing the company's strong position post-Iran conflict [3]. - HSBC also upgraded Align to buy from hold, raising the price target from 150 to 200, noting positive trends in Q4, particularly in adult aligner shipments [4]. Group 2: Technical Analysis - Align Technology's stock is forming a cup-with-handle base with a buy point at 199.06, although the base is deeper than normal [5]. - A trendline indicates an aggressive early entry point around 180, with shares climbing above the 50-day moving average [6]. - The stock has a Composite Rating of 81 and a 21-day average true range (ATR) of 4.05%, indicating significant price movement potential [7].

Core Viewpoint - Investors are evaluating Align Technology (ALGN) and West Pharmaceutical Services (WST) for potential undervalued stock opportunities in the Medical - Dental Supplies sector [1] Group 1: Company Valuation Metrics - ALGN has a forward P/E ratio of 15.38, while WST has a forward P/E of 30.42, indicating that ALGN may be more undervalued [5] - The PEG ratio for ALGN is 1.53, compared to WST's PEG ratio of 2.56, suggesting that ALGN offers better value relative to its expected earnings growth [5] - ALGN's P/B ratio is 3.06, while WST's P/B ratio is 5.42, further supporting the notion that ALGN is the more attractive investment based on valuation metrics [6] Group 2: Investment Outlook - Both ALGN and WST have a Zacks Rank of 2 (Buy), indicating a positive earnings outlook due to favorable analyst estimate revisions [3] - ALGN holds a Value grade of B, while WST has a Value grade of D, reinforcing the assessment that ALGN is the superior value option at this time [6]

The fund is expected to push for strategic measures aimed at boosting shareholder value as the company navigates weaker demand following its pandemic-era peak.Elliott Eyes Strategic Changes For Align TechnologyCiting people familiar with the matter, Bloomberg on Thursday reported that Elliott has accumulated one of the largest stakes in Align, positioning itself to influence the company’s corporate direction.The activist firm plans to engage with management to evaluate options that could help lift the compa ...

Market Overview - Global stocks are experiencing a significant decline due to rising oil and gas prices, raising concerns about inflation and economic growth amid escalating conflicts in the Middle East [1][9] - Brent crude oil prices have surged nearly 60% since the start of the conflict, reaching over $114 per barrel, while West Texas Intermediate (WTI) has seen a more muted increase [6][36] - The S&P 500 futures dropped 0.3%, and European equities fell 2.1%, heading towards their lowest levels of the year [1][19] Corporate News - Micron Technology reported strong earnings and guidance, nearly doubling the Street's Q3 EPS expectations, but its stock fell 5% due to global risk-off sentiment and high capital expenditure concerns [1][5] - Mining stocks underperformed as copper prices declined, and gold prices fell for the seventh consecutive day, impacting companies like Newmont and Freeport-McMoRan [5] - Canadian Solar's shares tumbled 19% after reporting a larger-than-expected fourth-quarter loss and a revenue forecast that missed analyst estimates [5] - Dlocal's shares rose 7% after beating expectations in its fourth-quarter results and announcing buyback plans, while Five Below gained 7% on positive sales forecasts [5] Central Bank and Economic Outlook - The Bank of Japan maintained its interest rates, signaling that the conflict in the Middle East has clouded the policy outlook, while the Federal Reserve's recent messaging indicates that further interest rate cuts are not guaranteed [8][11] - The market is pricing in potential rate hikes from the European Central Bank and the Bank of England due to rising inflation risks linked to the energy crisis [48][49] Geopolitical Impact - The ongoing conflict in the Middle East is causing significant disruptions to energy supplies, with attacks on key infrastructure leading to fears of stagflation [1][10] - President Trump's administration is considering deploying additional U.S. troops to the Middle East, and there are discussions about a substantial budget request to fund military operations in Iran [24][35]

Company Overview - Elliott Investment Management has acquired a significant stake in Align Technology Inc, the maker of Invisalign products, becoming one of its largest investors [1][2] - Align Technology's shares have decreased by over 75% since their peak in 2021 due to sluggish demand for dental products [2] Strategic Engagement - Elliott plans to engage with Align Technology to promote strategies aimed at boosting its stock price [2] - Analysts predict that demand in the dental sector may stabilize by 2026, but there are concerns regarding a full recovery in the broader market [2]

Elliott has built a significant stake in Align, the maker of Invisalign teeth-straightening products, sources say https://t.co/lAkX4jeZFC ...

Align Technology Inc (NASDAQ:ALGN) is among the best 3D printing stocks to buy according to hedge funds. On March 11, Align Technology Inc (NASDAQ:ALGN) CFO John Morici presented at the Barclays 28th Annual Global Healthcare Conference. At the conference, Morici discussed Align Technology’s growth prospects, strong cash position, strategic initiatives, and challenges. Align Technology Inc (ALGN) Sees Strong Growth Prospects in International Markets Among other things, the executive highlighted the compan ...

Upgrades Summary - Morgan Stanley upgraded Lemonade (LMND) to Overweight from Equal Weight with a price target of $85, increased from $80, citing the partnership with Tesla (TSLA) as a significant first step that provides Lemonade with a first-mover advantage in data analysis and practical experience [2] - Barclays upgraded Align Technology (ALGN) to Overweight from Equal Weight with an unchanged price target of $200, noting that the stock's risk/reward profile has improved due to a 15% pullback driven by the Middle East conflict from its February high [2] - Wells Fargo upgraded Dover (DOV) to Overweight from Equal Weight with a price target of $230, up from $210, indicating that U.S. macro data supports a short-cycle recovery [2] - Stifel upgraded Ichor Holdings (ICHR) to Buy from Hold with a price target of $55, increased from $30, expressing renewed confidence that the company's gross margin trajectory is entering an up-cycle sweet spot [2] - Piper Sandler upgraded Tandem Diabetes (TNDM) to Overweight from Neutral with a price target of $33, raised from $21, following an analysis of Tandem's pharmacy pricing benefits and international direct market opportunities [2]